Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma

Equality Impact Assessment (Guidance development) (PDF 143 KB)

Final draft guidance

Committee papers (PDF 2.77 MB)

Final appraisal document (PDF 208 KB)

Public committee slides (PDF 608 KB)

Final scope (PDF 200 KB)

Final stakeholder list (PDF 209 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 316 KB)

Equality impact assessment (Scoping) (PDF 121 KB)

Draft scope post referral (PDF 337 KB)

Draft matrix post referral (PDF 207 KB)